Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab
Open Access
- 28 November 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 47 (2) , 224-225
- https://doi.org/10.1093/rheumatology/kem299
Abstract
Sir, Progressive multifocal leucoencephalopathy (PML) is a rare but usually fatal demyelinating disease of the brain caused by JC papovavirus (JCV). At least 50–75% of the adult population are seropositive for JCV. When JCV reactivation occurs, focal plaques develop in central nervous system white matter. Viral proliferation causes lysis of oligodendrocytes and therefore rapid demyelination [1]. Rituximab is a relatively novel therapy for systemic lupus erythematosus (SLE) and PML has not previously been reported in a patient with SLE treated with rituximab.Keywords
This publication has 0 references indexed in Scilit: